You are here: Industry Insights > InnoCare

News List

InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Waldenström’s Macroglobulinemia in China March 14, 2022
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced recently...
InnoCare to Host 2021 Full Year Earnings Call on March 23, 2022 InnoCare Pharma
March 11, 2022
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases...
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development PharmaSources.com
January 07, 2022
InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company executives will attend the upcoming investor conferences organized by Morgan Stanley and UBS to share company’s latest development.
Orelabrutinib Data Presented at the 63rd Annual Meeting of ASH prnasia
December 14, 2021
InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that leading PIs presented latest data of BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH) Annual Meeting...
InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List prnasia
December 03, 2021
InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement Drug List (NRDL)...
InnoCare Announces the Clearance of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 by U.S. FDA prnasia
November 15, 2021
InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today the Investigational New Drug (IND) clearance of its SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase)...
InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH prnasia
November 09, 2021
InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company will present latest data of its BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH)...
InnoCare Announces Approval of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China prnasia
October 19, 2021
InnoCare Pharma (HKEX: 09969) announced today that the Company has received Investigational New Drug (IND) approval from the NMPA for its SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP-189...
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP in China prnasia
August 11, 2021
InnoCare Pharma, a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib by China National Medical Products Administration (NMPA) for starting ...
Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis drugs
July 16, 2021
Biogen Inc. (Nasdaq: BIIB) and InnoCare Pharma Limited (HKEX: 09969) today announced that they have entered into a license and collaboration agreement for orelabrutinib, an oral small molecule Bruton’s tyrosine kinase inhibitor (BTKi)

Previous page 1 2 3 4 5 6 Next page